Get the Stockscreener App
22.07
0.41%
0.09
After Hours:
22.07
Pharvaris Nv stock is traded at $22.07, with a volume of 280.32K.
It is up +0.41% in the last 24 hours and down -4.87% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$21.98
Open:
$22.26
24h Volume:
280.32K
Relative Volume:
1.64
Market Cap:
$1.41B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-7.8163
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
-5.08%
1M Performance:
-4.87%
6M Performance:
+83.92%
1Y Performance:
+11.86%
1-Day Range:
$21.57
$23.50
1-Week Range:
$21.57
$23.81
52-Week Range:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
22.07 | 1.41B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Has Pharvaris N.V. found a price floorWeekly Stock Summary & Accurate Buy Signal Alerts - newser.com
Can Pharvaris N.V. stock sustain free cash flow growthJuly 2025 Reactions & Growth Focused Stock Reports - newser.com
What analyst consensus says on Pharvaris N.V. stockEarnings Recap Report & Capital Efficient Trade Techniques - newser.com
What data driven models say about Pharvaris N.V.’s futureJuly 2025 Final Week & Free Community Consensus Stock Picks - newser.com
What’s next for Pharvaris N.V. stock price2025 Trading Recap & AI Forecasted Entry/Exit Points - newser.com
Can Pharvaris N.V. stock deliver sustainable ROEInsider Selling & AI Powered Market Trend Analysis - newser.com
Visual analytics tools that track Pharvaris N.V. performanceProfit Target & AI Enhanced Trading Alerts - newser.com
Pharvaris (NASDAQ:PHVS) Upgraded at Bank of America - Defense World
How to escape a deep drawdown in Pharvaris N.V.Weekly Investment Report & Verified Momentum Watchlists - newser.com
Will Pharvaris N.V. (9EN) stock outperform benchmarksJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
Pharvaris (NASDAQ:PHVS) Raised to Neutral at Bank of America - MarketBeat
Weiss Ratings Reiterates Sell (D-) Rating for Pharvaris (NASDAQ:PHVS) - MarketBeat
Chart based exit strategy for Pharvaris N.V.Market Movers & Verified Technical Signals - newser.com
B of A Securities Upgrades Pharvaris N.V. (PHVS) - Nasdaq
Building trade automation scripts for Pharvaris N.V.2025 Price Targets & Weekly High Return Stock Opportunities - newser.com
BofA Securities upgrades Pharvaris stock rating to Neutral on broader label potential - Investing.com Australia
Pharvaris NV (NASDAQ: PHVS) stock has achieved $25.44 in the past week - fostersleader.com
What drives Pharvaris NV stock priceHigh Yield Income Stocks & Fast Profit Trading Ideas - earlytimes.in
Is Pharvaris NV a good long term investmentTrendline Breakouts & Exceptional Return Stocks - earlytimes.in
Analyzing Pharvaris N.V. with multi timeframe chartsEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
How to forecast Pharvaris N.V. trends using time seriesTrade Volume Summary & High Accuracy Trade Signal Alerts - newser.com
Why pension funds invest in Pharvaris N.V. (9EN) stock2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
Combining price and volume data for Pharvaris N.V.July 2025 Breakouts & Weekly Watchlist of Top Performers - newser.com
Pharvaris (NASDAQ:PHVS) Shares Gap DownHere's What Happened - MarketBeat
Using Bollinger Bands to evaluate Pharvaris N.V.Share Buyback & Growth Focused Stock Reports - newser.com
Heatmap analysis for Pharvaris N.V. and competitors2025 Big Picture & Verified Entry Point Signals - newser.com
Is Pharvaris N.V. meeting your algorithmic filter criteria2025 Volatility Report & Risk Managed Investment Signals - newser.com
Is Pharvaris N.V. stock supported by strong cash flowsWeekly Trend Report & Low Risk High Reward Trade Ideas - newser.com
Can Pharvaris N.V. hit a new high this monthInsider Selling & Low Risk High Win Rate Stock Picks - newser.com
Will RAPIDe-3 Data Cement Deucrictibant's Role In HAE Treatment? - RTTNews
Pharvaris (NASDAQ:PHVS) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Pharvaris NV Stock Analysis and ForecastTrading Volume Trends & Low Cost Capital Gains - earlytimes.in
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):